.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) - Health
- Parenting
- Style and beauty
- Horoscopes
- Shopping
- Food
- Travel
- Autos
- Gift ideas
- Buying guides
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Private Companies
- Research
- Personal Finance
- Videos
- Watch Now
- Fantasy
- Daily fantasy
- NFL
- NBA
- MLB
- NHL
- College football
- College basketball
- Soccer
- NFL Draft
- Yahoo Sports AM
- Show all
© 2025 All rights reserved.
BioLineRx upgraded to Buy from Hold at JonesResearch
TipRanks
Sat, May 31, 2025, 5:46 AM 1 min read
In This Article:
JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus chemo in first line pancreatic cancer where seven of 11 patients responded to therapy and 10 of 11 achieved disease control, the analyst tells investors in a research note. With these results, the firm believes BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial assuming favorable Phase II results. It sees potential for more favorable stock momentum first line pancreatic cancer “in play.”
Confident Investing Starts Here:
-
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLRX:
Disclaimer & DisclosureReport an Issue
-
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial
-
BioLineRx announces new data from Phase 2 combination trial of motixafortide
-
BioLineRx ADR: Positive Earnings Call Highlights and Challenges
-
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating
Terms and Privacy Policy
Comments